
SUMMARY

[0006a] In an aspect of the present disclosure, there is provided a use of a compound of the following structure in manufacture of a medicament for treating cancer:



wherein X is O;

R_1 is a hydrogen;

each of R_2, R_3, R_4, R_5, and R_6 is independently a hydrogen or a hydroxyl;

R_8 and R_9 are each hydrogen; z is 1 or 2; and

wherein the compound is to be administered at a dose of 0.1 mg/day to 1 g/day.


[0006b] In a further aspect of the present disclosure, there is provided a use of a compound as defined herein in the manufacture of a medicament for treating chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), breast cancer, and colon cancer.

[0007] The present disclosure generally encompasses compounds that inhibit a specific tyrosine kinase (*i.e.*, Src kinase) and compositions including such compounds as well as combinations of such compositions with known cancer drugs to treat and prevent cancer.

[0008] In another example, the present disclosure encompasses methods of use of the compositions including active compounds or derivatives and metabolites thereof in any disease conditions where Src tyrosine kinase or Src family kinases (SFKs) activity has been implicated, for example, but not limited to, the development, maintenance, progression, and metastatic spread of cancers.

[0009] In certain examples, the compound and compositions are effective against human cancer and tumor cells including, but not limited to, those associated with chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), breast cancer (e.g., Triple negative, HER2+ etc), and colon cancer.

[0010] In one example, the Compounds Of The Present Disclosure includes compounds of the following structure:



Formula I

[0011] wherein X is O or S;

[0012] R_1 is a hydrogen, or a substituted or unsubstituted substituent including but not limited to lower alkyl, a lower alkenyl, a lower alkynyl, $-(CH_2)_mR_7$, $(CH_2)_m$-OH, $-(CH_2)_m$-O-lower alkyl, $-(CH_2)_m$-O-lower alkenyl, $-(CH_2)_n$-O-$(CH_2)_m$-R_7, $-(CH_2)_m$-SH, $-(CH_2)_m$-S-lower alkyl, $-(CH_2)_m$-S-lower alkenyl, $-(CH_2)_n$-S-$(CH_2)_m$-R_7

[0013] each of R_2-R_6 is independently a hydrogen, a hydroxyl, a halogen, a lower alkyl, a lower